---
title: "Brief News: Legend Biotech's Revenue Soars, Sales Momentum for Cancer Therapies Continues to Strengthen"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286208783.md"
description: "Legend Biotech's revenue in the first quarter increased by 56% year-on-year, reaching USD 305.1 million, mainly due to strong sales of the cancer therapy Carvykti, developed in collaboration with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The therapy is sold in 18 markets, with total sales reaching USD 597 million, a year-on-year increase of 62%. The company's net loss was USD 54.3 million, nearly halving compared to the same period last year. Following the earnings report, Legend Biotech's stock price rose by 10.5%, with a cumulative increase of 31% for the year"
datetime: "2026-05-13T06:35:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286208783.md)
  - [en](https://longbridge.com/en/news/286208783.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286208783.md)
---

# Brief News: Legend Biotech's Revenue Soars, Sales Momentum for Cancer Therapies Continues to Strengthen

Biopharmaceutical company **Legend Biotech Corporation** (LEGN.US) announced on Tuesday that, thanks to strong sales of the cancer therapy Carvykti developed in collaboration with **Johnson & Johnson** (JNJ.US) subsidiary Janssen Pharmaceuticals, its first-quarter revenue surged 56% year-over-year to $305.1 million.

The company's approximately $298 million in revenue this quarter primarily came from its collaboration with Janssen. The therapy is currently sold in 18 global markets, including recent launches in Poland, the Czech Republic, and Australia. Total sales of Carvykti for the quarter reached $597 million, a year-over-year increase of 62%.

The company's latest quarterly net loss was $54.3 million, narrowing nearly half from a loss of $101 million in the same period last year. Adjusted quarterly losses shrank more than half from $27 million in the same period last year to $10.5 million.

After the earnings report was released, Legend Biotech's stock listed in New York rose 10.5% on Tuesday, with a cumulative increase of 31% year-to-date.

_Yang Ge_

### Related Stocks

- [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Barclays Reaffirms Their Buy Rating on Legend Biotech (LEGN)](https://longbridge.com/en/news/286227290.md)
- [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)
- [These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results](https://longbridge.com/en/news/286301750.md)
- [Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says](https://longbridge.com/en/news/286290495.md)